Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266706 | 1.00 | CTSS (0.51) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL1162807 | 1.00 | CTSS (0.51) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL16174131 | 0.89 | CTSS (0.49) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL16171661 | 0.89 | CTSS (0.49) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL4076640 | 0.88 | CTSS (0.45) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL27813793 | 0.87 | CTSS (0.47) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL17723343 | 0.87 | CTSS (0.47) | CTSSCTSKS1PR3CYP3A4CYP2D6 | |
| SCHEMBL8513252 | 0.86 | CTSS (0.52) | CTSSCTSKS1PR3TSHRATM | |
| SCHEMBL843924 | 0.86 | CTSS (0.52) | CTSSCTSKS1PR3ATMPPARA | |
| SCHEMBL191986 | 0.86 | CTSS (0.52) | CTSSCTSKS1PR3ATMPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338897-A | Compositions and methods for providing health benefits in animals using amino acid blends | 雀巢产品有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-4262776-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2023-10-25 | — | — | EP | claimed |
| CN-116546981-A | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof and at least one thymol and/or carvacrol | 雀巢产品有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-116456965-A | Compositions and methods using at least one glycine or derivative thereof and at least one large neutral amino acid and/or cationic amino acid or precursor thereof | 雀巢产品有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-115957294-A | Beneficial effects of supplementation with N-acetylcysteine and glycine to improve glutathione levels | 贝勒医学院 | 2023-04-14 | — | — | CN | claimed |
| WO-2022128870-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2022-06-23 | — | — | WO | claimed |
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4405686-A1 | METHOD FOR DETECTING AND/OR QUANTIFYING MOOD DISORDER AND/OR IMPROVEMENTS OF THE MOOD DISORDER STATUS USING CONJUGATED BILE ACIDS AS BIOMARKER AND IMPROVED METHODS AND COMPOSITIONS THEREOF | Société des Produits Nestlé S.A. (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-118338897-A | Compositions and methods for providing health benefits in animals using amino acid blends | 雀巢产品有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117940774-A | Methods of using conjugated bile acids as biomarkers for detecting and/or quantifying mood disorders and/or mood disorder status improvement and improved methods and compositions thereof | 雀巢产品有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4262776-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2023-10-25 | — | — | EP | disclosed |
| CN-116546981-A | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof and at least one thymol and/or carvacrol | 雀巢产品有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116456965-A | Compositions and methods using at least one glycine or derivative thereof and at least one large neutral amino acid and/or cationic amino acid or precursor thereof | 雀巢产品有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
| US-7132533-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK1, CHEK2, CHKA | CTSS 1118/4885CTSK 390/4885S1PR3 1604/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | CTSS 1108/4885CTSK 375/4885S1PR3 1743/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | CTSS 1040/4885CTSK 365/4885S1PR3 1315/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | CTSS 4722/4885CTSK 4207/4885S1PR3 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.